A Phase 3 interventional study of Maxigesic IV and IV Acetaminophen in Post Operative Pain, sponsored by AFT Pharmaceuticals, Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-07-06.
Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies testing acetaminophen in Pain, Postoperative — 11 open to participants now, 13 under way, 1 of them phase 3. Acetaminophen · Pain, Postoperative.
Among the 118 studies testing acetaminophen in Pain, Postoperative, this one is the 14th largest by enrollment, is one of 6 that started in 2016, is one of 20 in phase 3, and was the 47th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,231 are open to participants now.
Browse Pain, Postoperative studies →11 of the 118 studies testing acetaminophen in Pain, Postoperative are open now, in 4 countries. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–80
University of Puerto Rico · Sites in Puerto Rico
Ages 21–65
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+ · Women only · Healthy volunteers
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
Rothman Institute Orthopaedics · Sites in United States
Ages 18+
By country, each count listing its studies:
Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →
Of the 679 Pain, Postoperative studies recruiting now, 240 (35%) set no upper age limit and 329 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 12 · Phase 3 23 · Phase 4 53
First in 2002; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 276 is above the median of 75 across 4,829 interventional studies indexed under Pain, Postoperative.
Median enrollment 90 across the 118 interventional studies. Of the 88 that completed or were terminated, 41 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 118 have an industry lead sponsor. The 10 most frequent:
AFT Pharmaceuticals, Ltd. is the lead sponsor of 9 studies on the registry; 4 are open to participants now.
AFT Pharmaceuticals, Ltd. has 3 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
6 of the studies testing acetaminophen in Pain, Postoperative that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07571252University of Puerto RicoImpact of Preemptive Analgesia on Postoperative Pain in Orthognathic Surgery | 2026-12 |
| NCT06997016Baylor Research InstituteEnhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients | 2027-06 |
| NCT03105518Brigham and Women's HospitalPredictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 2027-06-30 |
| NCT06613178McGill University Health Centre/Research Institute of the McGill University Health CentreIntravenous Acetaminophen After Cardiac Surgery - Definitive Study | 2027-07-01 |
| NCT07720791Konya City HospitalAcetaminophen vs Placebo for Postoperative Analgesia After Abdominal Surgery | 2027-07-15 |
Add all 6 to your calendar (.ics) → With an account.
Among the 118 studies testing acetaminophen in Pain, Postoperative, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine the clinical efficacy and safety of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV for the treatment of acute postoperative pain after bunionectomy
AFT Pharmaceuticals Ltd. has been developing a fixed-dose combination of acetaminophen 1000mg and ibuprofen 300mg/100mL solution for infusion (Maxigesic IV) for the temporary relief of postoperative pain, when administration by intravenous route is clinically justified by an urgent need to treat pain or hyperthermia and/or when other routes of administration not possible.
A phase 3 efficacy study (AFT-MXIV-07) is proposed to determine the analgesic effects of the fixed dose combination product Maxigesic IV versus its individual components (acetaminophen IV and ibuprofen IV) and placebo in participants with acute post-operative pain after bunionectomy.
The primary efficacy objective is to determine the efficacy of Maxigesic IV, acetaminophen IV, Ibuprofen IV versus placebo IV as measured by the summed pain intensity difference (SPID) (calculated as a time-weighted average) over 0-48 hours (SPID-48) after time 0.
Other secondary efficacy endpoints are:
VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0 VAS Pain intensity score at each scheduled assessment time point VAS SPID over 0 to 6 hours (SPID-6), over 0 to 12 hours (SPID-12), and over 0 to 24 hours (SPID-24) after Time 0
Summed pain relief (TOTPAR) (calculated as a time-weighted average) over 0 to 6 hours (TOTPAR-6), over 0 to 12 hours (TOTPAR-12), over 0 to 24 hours (TOTPAR-24) after Time 0, and over 0 to 48 hours (TOTPAR-48) after Time 0
Time to onset of analgesia (measured as time to perceptible pain relief confirmed by meaningful pain relief) using the two-stopwatch method Pain relief score on a 5-point categorical scale at each scheduled time point after Time 0
Peak pain relief
Time to peak pain relief
Time to first perceptible pain relief
Time to meaningful pain relief
Proportion of subjects using rescue medication
Time to first use of rescue medication (duration of analgesia)
Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours Patient's global evaluation of study drug
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
If female, is either not of childbearing potential (defined as for at least 1 year or surgically sterile [bilateral tubal ligation, bilateral oophorectomy, or hysterectomy]) or practicing 1 of the following medically acceptable methods of :
Hormonal methods such as oral, implantable, injectable, or transdermal contraceptives for a minimum of 1 full cycle (based on the subject's usual menstrual cycle period) before study drug administration.
Total abstinence from sexual intercourse since the last menses before study drug administration through completion of final study visit.
Intrauterine device (IUD). Double-barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous acetaminophen1000 mg + intravenous ibuprofen 300 mg/100 ml solution for infusion, 100 mL, every 6 hours for 48 hours
Drug: Maxigesic IV
IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL. every 6 hours for 48 hours
Drug: IV Acetaminophen
IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL every 6 hours for 48 hours
Drug: IV Ibuprofen
Placebo IV- 100 mL saline for infusion, 100mL every 6 hours for 48 hours
Drug: Placebo IV
Drug pages: Acetaminophen · Ibuprofen
IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Also known as: Maxigesic
IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Also known as: Acetaminophen
IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
Also known as: Ibuprofen
Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
Also known as: Placebo
Summed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).
A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced. The extent of pain relief can then be calculated by the Area Under the Curve the PID scores (also referred to as the Sum of Pain Intensity Differences \[SPID\]). SPID48 scores were adjusted by the time interval from baseline to the final VAS score used in the SPID, using the following formula: Time-adjusted SPID48 (mm) = SPID (mm\*hr) / Time (hr) In the event that a patient required rescue medication, the SPID was calculated up until the first Pre-Rescue VAS pain assessment (inclusive).
Time frame: 48 hours after the first dose
VAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm).
VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0. A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced.
Time frame: 48 hours after the first dose
VAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced.
VAS Pain intensity score at each scheduled assessment time point VAS pain intensity score-marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). A high VAS score indicates a more intensive pain level experienced.
Time frame: 48 hours after the first dose
SPID-6, SPID-12, SPID-24-VAS SPID Over 0 to 6 Hours (SPID-6), Over 0 to 12 Hours (SPID-12), and Over 0 to 24 Hours (SPID-24) After Time 0 (=the First Dose)
Time adjusted SPID-6, SPID-12, SPID-24 were derived in a similar manner to the Time-adjusted SPID-48 (i.e. up until the first Pre-Rescue VAS inclusive). Please see the primary outcome measure descriptions. Each of these variables were derived from VAS (Visual Analogue Scale) scores recorded prior to the first dose of rescue medication in the first 6 (to calculate SPID6), 12 (to calculate SPID12) or 24 hours (to calculate SPID24) of the study. VAS pain intensity scores were obtained by marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). The VAS was completed at rest.
Time frame: 6, 12, 24 hours after the first dose
TOTPAR-6, TOTPAR-12, TOTPAR-24, TOTPAR-48
Total Pain Relief (TOTPAR) is a measure of total Area Under the Curve of Pain Relief scores. In the event that a patient required rescue medication, the TOTPAR endpoints were calculated using Pain Relief Assessments recorded prior to the first dose of rescue (i.e. inclusive of the first pre-rescue Pain Relief score). Pain relief scores were obtained by marking on a 5-point categorical rating at scheduled time points. The high score means more pain relief experienced: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Each of these variables were derived from pain relief scores recorded prior to the first dose of rescue medication in the first 6 (0-48), 12 (0-48), 24 (0-48) or 48 (0-48) hours of the study.
Time frame: 6, 12, 24, 48 hours after the first dose
Time to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method
Two-stopwatch method 1. Start two stopwatches ('Stopwatch A' and 'Stopwatch B') at the same time that the infusion of study drug is initiated. This is Time 0. 2. The participant is given 'Stopwatch A' and instructed to "Stop 'Stopwatch A' when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now." (Perceptible Pain Relief) 3. When the participant stops the 'Stopwatch A', the participant then was asked "Do you consider the pain relief you experienced meaningful?" 4. If the participant answered "No", then the participant was given the "Stopwatch B" and instructed to "Stop 'Stopwatch B' when you feel the pain relief is meaningful to you" (Meaningful Pain Relief) 5. If the subject did not experience "perceptible pain relief, they would retain 'Stopwatch A' for the entire 6 hour evaluation period.
Time frame: 6 hours
Percentage of Participants With Complete Pain Relief
Pain relief score was assessed on a 5-point categorical scale at each scheduled time point after Time 0: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Assessed at scheduled time points: * 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6 hours after the first dose of the study drug * Immediately before and 2 hours after each subsequent dose (doses 2-8) of the study drug while awake * At the end of 48 hours of double-blind treatment period * Immediately before taking each dose of the rescue medication if additional analgesia is required. * At the time of withdrawal (if applicable)
Time frame: 48 hours after the first dose
Percentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue
Peak Pain Relief was assessed on Pain Relief scores (on a 5 point categorical rating-please see outcome measure description No. 7) recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). The percentage of participants who achieve the peak pain relief was summarized.
Time frame: 48 hours after the first dose
Time to Peak Pain Relief
Time to peak pain relief-Peak Pain Relief was assessed on Pain Relief scores recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). Time for participants who experienced peak pain relief was summarized. Note: For the reader to interpret this outcome measure, a very short Time to Peak Pain Relief indicates the absence of analgesic effect for a treatment because peak pain relief was determined prior to the first dose of rescue medication (or 48 hours if no rescue medication was used).
Time frame: 48 hrs after the first dose
Percentage of Subjects Using Rescue Medication
The percentage of participants who used at lease one dose of rescue medication was summarized in each treatment group
Time frame: 48 hrs after the first dose
Time to the First Dose of Rescue Medication
Time to first use of rescue medication (duration of analgesia)
Time frame: 48 hrs
Total Use of Rescue Medication
Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours
Time frame: 24, 48 hrs after the first dose
The Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug
At the end of 48 hours study period, participants will be asked to " How do you rate the study medication?" on a 5 point categorical scale: 1. Poor 2. Fair 3. Good 4. Very Good 5. Excellent The high score means the participants believed that a better treatment for pain relief received.
Time frame: 48 hrs after the first dose
Number of Participants With Treatment Emergent Adverse Events (AEs)
Treatment-emergent Adverse events coded to MedDRA v 20.0 Preferred Term and System Organ Class Code were tabulated as the counts and percentages by treatment group.
Time frame: Day 7
| Milestone | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Started | 75 | 75 | 76 | 50 |
| Completed | 75 | 73 | 73 | 50 |
| Not completed | 0 | 2 | 3 | 0 |
A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced. The extent of pain relief can then be calculated by the Area Under the Curve the PID scores (also referred to as the Sum of Pain Intensity Differences \[SPID\]). SPID48 scores were adjusted by the time interval from baseline to the final VAS score used in the SPID, using the following formula: Time-adjusted SPID48 (mm) = SPID (mm\*hr) / Time (hr) In the event that a patient required rescue medication, the SPID was calculated up until the first Pre-Rescue VAS pain assessment (inclusive).
| score on a scale | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Summed Pain Intensity Difference (SPID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). | 23.4 (-34.08 to 74.17) | 10.4 (-26.78 to 65.43) | 9.5 (-30.68 to 79.98) | -1.3 (-22.42 to 47.50) |
VAS Pain intensity difference (PID) at each scheduled assessment time point after Time 0. A Pain Intensity Difference (PID) is the difference between the Visual Analogue Scale (VAS) pain intensity score recorded at baseline and a score recorded at any time after the first dose of study medication. Taken together, a patient's PID scores capture the pain relief profile attributable to the assigned study medication. A high PID score indicates a better pain relief experienced.
| score on a scale | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| VAS Pain Intensity Difference (PID)-Calculated From the Pain Intensity Scores Recorded on a 100mm Long VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). | 52.50 ± 2.73 | 38.95 ± 2.69 | 45.04 ± 3.05 | 37.24 ± 3.90 |
VAS Pain intensity score at each scheduled assessment time point VAS pain intensity score-marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). A high VAS score indicates a more intensive pain level experienced.
| score on a scale | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| VAS Pain Intensity Score-marking on a 100 mm VAS Scale With Anchors for "no Pain" (0 mm) and "Worst Pain Imaginable" (100 mm). A High VAS Score Indicates a More Intensive Pain Level Experienced. | 18.43 ± 2.85 | 29.28 ± 2.59 | 27.21 ± 3.22 | 28.22 ± 3.48 |
Time adjusted SPID-6, SPID-12, SPID-24 were derived in a similar manner to the Time-adjusted SPID-48 (i.e. up until the first Pre-Rescue VAS inclusive). Please see the primary outcome measure descriptions. Each of these variables were derived from VAS (Visual Analogue Scale) scores recorded prior to the first dose of rescue medication in the first 6 (to calculate SPID6), 12 (to calculate SPID12) or 24 hours (to calculate SPID24) of the study. VAS pain intensity scores were obtained by marking on a 100 mm VAS scale with anchors for "no pain" (0 mm) and "worst pain imaginable" (100 mm). The VAS was completed at rest.
| score on a scale | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| SPID 6 | 20.10 (-34.08 to 61.14) | 10.13 (-26.78 to 65.43) | 9.01 (-30.68 to 61.92) | -1.49 (-22.42 to 47.50) |
| SPID 12 | 20.63 (-34.08 to 71.60) | 9.42 (-26.78 to 65.43) | 8.44 (-30.68 to 69.40) | -1.66 (-22.42 to 47.50) |
| SPID 24 | 21.99 (-34.08 to 77.47) | 9.59 (-26.78 to 65.43) | 8.64 (-30.68 to 73.19) | -1.54 (-22.42 to 47.50) |
Total Pain Relief (TOTPAR) is a measure of total Area Under the Curve of Pain Relief scores. In the event that a patient required rescue medication, the TOTPAR endpoints were calculated using Pain Relief Assessments recorded prior to the first dose of rescue (i.e. inclusive of the first pre-rescue Pain Relief score). Pain relief scores were obtained by marking on a 5-point categorical rating at scheduled time points. The high score means more pain relief experienced: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Each of these variables were derived from pain relief scores recorded prior to the first dose of rescue medication in the first 6 (0-48), 12 (0-48), 24 (0-48) or 48 (0-48) hours of the study.
| score on a scale*hour | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| TOTPAR 6 | 6.84 (0.0 to 22.6) | 4.59 (0.0 to 22.5) | 3.34 (0.0 to 21.2) | 1.60 (0.0 to 11.0) |
| TOTPAR 12 | 11.86 (0.0 to 46.6) | 6.74 (0.0 to 38.9) | 4.46 (0.0 to 35.2) | 1.82 (0.0 to 18.0) |
| TOTPAR 24 | 22.13 (0.0 to 94.6) | 8.66 (0.0 to 66.5) | 6.51 (0.0 to 71.2) | 2.49 (0.0 to 47.1) |
| TOTPAR 48 | 43.98 (0.0 to 190.5) | 13.28 (0.0 to 138.5) | 11.95 (0.0 to 131.2) | 4.51 (0.0 to 139.2) |
Two-stopwatch method 1. Start two stopwatches ('Stopwatch A' and 'Stopwatch B') at the same time that the infusion of study drug is initiated. This is Time 0. 2. The participant is given 'Stopwatch A' and instructed to "Stop 'Stopwatch A' when you first feel any pain relief whatsoever. This does not mean you feel completely better, although you might, but when you first feel any relief in the pain you have now." (Perceptible Pain Relief) 3. When the participant stops the 'Stopwatch A', the participant then was asked "Do you consider the pain relief you experienced meaningful?" 4. If the participant answered "No", then the participant was given the "Stopwatch B" and instructed to "Stop 'Stopwatch B' when you feel the pain relief is meaningful to you" (Meaningful Pain Relief) 5. If the subject did not experience "perceptible pain relief, they would retain 'Stopwatch A' for the entire 6 hour evaluation period.
| minutes | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Time to the Onset of Analgesia-Time to Onset of Analgesia (Measured as Time to Perceptible Pain Relief Confirmed by Meaningful Pain Relief) Using the Two-stopwatch Method | 9.4 (6.5 to 11.8) | 23.9 (13.5 to 39.2) | 13.8 (6.5 to 24.4) | 0 (9.9 to 0) |
Pain relief score was assessed on a 5-point categorical scale at each scheduled time point after Time 0: 0 = No pain relief (the pain is the same, or worse, than the starting pain) 1. = A little pain relief (the pain is less than half gone) 2. = some pain relief (the pain is about half gone) 3. = A lot pain relief (the pain is more than half gone) 4. = Complete pain relief (the pain is completely gone) Assessed at scheduled time points: * 5, 10, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 5, 6 hours after the first dose of the study drug * Immediately before and 2 hours after each subsequent dose (doses 2-8) of the study drug while awake * At the end of 48 hours of double-blind treatment period * Immediately before taking each dose of the rescue medication if additional analgesia is required. * At the time of withdrawal (if applicable)
| Participants | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Percentage of Participants With Complete Pain Relief | 29 | 7 | 16 | 4 |
Peak Pain Relief was assessed on Pain Relief scores (on a 5 point categorical rating-please see outcome measure description No. 7) recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). The percentage of participants who achieve the peak pain relief was summarized.
| Participants | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Percentage of Participants Who Obtained a Peak Pain Relief -Value of 3 ('A Lot of Relief') or 4 ('Complete Relief') Prior to the First Dose of Rescue | 22 | 11 | 4 | 3 |
Time to peak pain relief-Peak Pain Relief was assessed on Pain Relief scores recorded up until the first dose of rescue (First Pre-Rescue Pain Relief score inclusive). Time for participants who experienced peak pain relief was summarized. Note: For the reader to interpret this outcome measure, a very short Time to Peak Pain Relief indicates the absence of analgesic effect for a treatment because peak pain relief was determined prior to the first dose of rescue medication (or 48 hours if no rescue medication was used).
| hours | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Time to Peak Pain Relief | 4.00 ± 1.17 | 2.46 ± 0.86 | 1.47 ± 0.55 | 0.91 ± 0.60 |
The percentage of participants who used at lease one dose of rescue medication was summarized in each treatment group
| Participants | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Percentage of Subjects Using Rescue Medication | 56 | 70 | 70 | 48 |
Time to first use of rescue medication (duration of analgesia)
| hours | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Time to the First Dose of Rescue Medication | 12.98 ± 1.87 | 5.62 ± 0.83 | 3.09 ± 0.35 | 2.92 ± 0.53 |
Total use of rescue analgesia over 0 to 24 hours and over 0 to 48 hours
| mg | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Total Dose in 48 hrs | 22.9 ± 2.4 | 33.1 ± 2.7 | 32.4 ± 2.7 | 44.7 ± 3.8 |
| Total Dose in 24 hrs | 17.2 ± 1.7 | 23.7 ± 1.6 | 22.1 ± 1.4 | 29.6 ± 2.0 |
At the end of 48 hours study period, participants will be asked to " How do you rate the study medication?" on a 5 point categorical scale: 1. Poor 2. Fair 3. Good 4. Very Good 5. Excellent The high score means the participants believed that a better treatment for pain relief received.
| Participants | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| The Percentage of Participants Who Evaluated Their Study Drug as " Excellent" on a 5-point Categorical Scale Global Evaluation of Study Drug | 24 | 5 | 8 | 1 |
Treatment-emergent Adverse events coded to MedDRA v 20.0 Preferred Term and System Organ Class Code were tabulated as the counts and percentages by treatment group.
| Participants | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (AEs) | 52 | 45 | 58 | 39 |
Collected over Participants were followed up for adverse events during the 48 hour study period. Any AEs which were not resolved by the end of the 48 hour study period were followed up at 30 days.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maxigesic IV | 0/75 (0%) | 0/75 (0%) | 52/75 (69.3%) |
| IV Acetaminophen | 0/75 (0%) | 0/75 (0%) | 45/75 (60%) |
| IV Ibuprofen | 0/76 (0%) | 0/76 (0%) | 58/76 (76.3%) |
| Placebo IV | 0/50 (0%) | 0/50 (0%) | 39/50 (78%) |
| Event | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 22/75 | 25/75 | 26/76 | 16/50 |
| VomitingGastrointestinal disorders | 16/75 | 11/75 | 5/76 | 1/50 |
| HeadacheNervous system disorders | 4/75 | 5/75 | 5/76 | 10/50 |
| DizzinessNervous system disorders | 13/75 | 7/75 | 7/76 | 8/50 |
| Infusion site extravasationGeneral disorders | 2/75 | 2/75 | 5/76 | 7/50 |
| Infusion site painGeneral disorders | 10/75 | 0/75 | 7/76 | 1/50 |
| ConstipationGastrointestinal disorders | 4/75 | 4/75 | 4/76 | 4/50 |
| SomnolenceNervous system disorders | 5/75 | 6/75 | 6/76 | 3/50 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/75 | 1/75 | 0/76 | 4/50 |
| PruritusSkin and subcutaneous tissue disorders | 5/75 | 3/75 | 4/76 | 2/50 |
| Age, Continuous(years) | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV | Total |
|---|---|---|---|---|---|
| Mean | 42.3 ± 11.6 | 41.9 ± 12.5 | 43.3 ± 12.3 | 41.7 ± 12.7 | 42.4 ± 12.2 |
| Sex: Female, Male(Participants) | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV | Total |
|---|---|---|---|---|---|
| Female | 62 | 58 | 65 | 40 | 225 |
| Male | 13 | 17 | 11 | 10 | 51 |
| Ethnicity (NIH/OMB)(Participants) | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 18 | 18 | 15 | 7 | 58 |
| Not Hispanic or Latino | 56 | 56 | 60 | 41 | 213 |
| Unknown or Not Reported | 1 | 1 | 1 | 2 | 5 |
| Region of Enrollment(Participants) | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV | Total |
|---|---|---|---|---|---|
| United States | 75 | 75 | 76 | 50 | 276 |
| Baseline Pain Intensity Level(scores on a 100mm long scale) | Maxigesic IV | IV Acetaminophen | IV Ibuprofen | Placebo IV | Total |
|---|---|---|---|---|---|
| Mean | 69.3 ± 15.8 | 66.2 ± 14.2 | 68.9 ± 14.4 | 68.1 ± 15.8 | 68.1 ± 15.0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — It is not planned to publish individual participant data.
Ran from Oct 2016 to primary completion in Jun 2017, 8 months.
Results were first posted in Jul 2021, 4 years after primary completion. A results delay was requested in Oct 2018.
Of 43 industry-sponsored phase 3 interventional studies under Pain, Postoperative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 8 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 8 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Acetaminophen · Ibuprofen
AFT Pharmaceuticals, Ltd.